Daclizumab

Category: Immunosuppressive

Daclizumab Overview

Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[2][3][1] Contents 1 Medical uses 1.1 Discontinued use...

Read more Daclizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daclizumab

Recent Daclizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Daclizumab: (1 result)

Sorted by National Drug Code

• 0074-0034 Zinbryta 150 mg/ml Subcutaneous Injection, Solution by Abbvie

Other drugs which contain Daclizumab or a similar ingredient: (2 results)

• ZENAPAX Daclizumab
• ZINBRYTA Daclizumab1 discussion

Related Daclizumab Topics: